CClinicalTrials.gg
Sign In
CompletedNCT03944031Updated Apr 22, 2020

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

A Phase 1 interventional study of LY3372689 and [18F]LSN3316612 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2020, 6 years 7 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study uses imaging to evaluate how LY3372689 binds to a protein in the brain. This study will be conducted in healthy participants and will last up to approximately 25 days after enrollment. Screening must be completed within 28 days prior to enrollment.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.

Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Overtly healthy males or females who cannot get pregnant
  • Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/m²), inclusive, at screening
  • Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
  • Have veins and arteries suitable for protocol required blood sampling

Exclusion criteria

Exclusion Criteria:

  • Have a history of head injury or contraindications to undergoing magnetic resonance imaging (MRI) examination
  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
  • Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study
  • Have long exposure to sunlight routinely or use tanning beds regularly
  • Participate in regular vigorous exercise
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    LY3372689 + [18F]LSN3316612

    LY3372689 administered orally followed by \[18F\]LSN3316612 PET tracer administered intravenously (IV) approximately 2 - 72 hours later.

    Drug: LY3372689 · Diagnostic Test: [18F]LSN3316612

Interventions

  • DrugLY3372689

    Administered orally.

  • Diagnostic test[18F]LSN3316612

    Administered IV.

    Also known as: [18F]MNI-1068

06

What researchers measure

Primary outcomes

  1. Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO)

    Percent OGA EO

    Time frame: Predose Scan (Days -14 to -1)

  2. Percent OGA EO

    Percent OGA EO

    Time frame: Postdose Scan 1 (Days 1 - 4)

  3. Percent OGA EO

    Percent OGA EO

    Time frame: Postdose Scan 2 (Days 2 - 4)

07

Study locations

1 site
  • Invicro, Institute for Neurodegenerative Disorders
    New Haven, Connecticut 06510, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03944031
Lead sponsor
Eli Lilly and Company
Responsible party
Sponsor
First posted
May 9, 2019
Start date
May 8, 2019
Primary completion
Feb 19, 2020
Completion
Feb 19, 2020
Last update
Apr 22, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Eli Lilly and Company

Start the discussion